Can a traditional chinese granule ease a common cancer treatment side effect?
NCT ID NCT07355361
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding Huaier Granule to standard care can reduce proteinuria (excess protein in urine) in breast cancer patients who developed it as a side effect of immunotherapy or anti-angiogenic therapy. About 120 women will be randomly assigned to receive either standard care alone or standard care plus Huaier Granule for up to 24 weeks. The main goal is to see if the combination improves proteinuria treatment response after 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Huaier Granule
What this could lead to
If it works, this could offer a new way to manage proteinuria as a side effect of cancer treatment, potentially improving quality of life for breast cancer patients.
What could go wrong
This is a small Phase 2 trial, so results are preliminary. The granule may not reduce proteinuria better than standard care, and its long-term safety is not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROTEINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••